Education
About Us
Working with TipRanks
Follow Us
3D Medicines, Inc. (HK:1244)
:1244
1244 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.60 - HK$8.38
Previous CloseN/A
Volume120.00K
Average Volume (3M)284.72K
Market Cap
HK$957.84M
Enterprise ValueHK$539.33M
Total Cash (Recent Filing)¥696.74M
Total Debt (Recent Filing)¥175.70M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Aug 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding258,177,000
10 Day Avg. Volume98,850
30 Day Avg. Volume284,716
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
3D Medicines, Inc. News
PremiumCompany Announcements
3D Medicines Announces Board Composition and Governance Structure
PremiumCompany Announcements
3D Medicines Inc. Forms Nomination Committee for Enhanced Governance
PremiumCompany Announcements
3D Medicines Inc. Reports 2024 Financial Results Amid Market Challenges
PremiumCompany Announcements
3D Medicines Inc. Schedules Board Meeting for Financial Review
PremiumCompany Announcements
3D Medicines Inc. Appoints New Chief Commercial Officer
PremiumCompany Announcements
3D Medicines Faces Asset Freeze Amid Civil Proceedings---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.02%
Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors
1244 FAQ
What was 3D Medicines, Inc.’s price range in the past 12 months?
3D Medicines, Inc. lowest stock price was HK$1.60 and its highest was HK$8.38 in the past 12 months.
What is 3D Medicines, Inc.’s market cap?
3D Medicines, Inc.’s market cap is HK$957.84M.
When is 3D Medicines, Inc.’s upcoming earnings report date?
3D Medicines, Inc.’s upcoming earnings report date is Aug 22, 2025 which is in 117 days.
How were 3D Medicines, Inc.’s earnings last quarter?
3D Medicines, Inc. released its earnings results on Mar 31, 2025. The company reported -HK$0.351 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.351.
Is 3D Medicines, Inc. overvalued?
According to Wall Street analysts 3D Medicines, Inc.’s price is currently Overvalued.
Does 3D Medicines, Inc. pay dividends?
3D Medicines, Inc. does not currently pay dividends.
What is 3D Medicines, Inc.’s EPS estimate?
3D Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 3D Medicines, Inc. have?
3D Medicines, Inc. has 258,177,000 shares outstanding.
What happened to 3D Medicines, Inc.’s price movement after its last earnings report?
3D Medicines, Inc. reported an EPS of -HK$0.351 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.266%.
Which hedge fund is a major shareholder of 3D Medicines, Inc.?
Currently, no hedge funds are holding shares in HK:1244
---
3D Medicines, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.77%
12-Months-Change
Fundamentals
Return on Equity
-21.22%
Trailing 12-Months
Asset Growth
-17.72%
Trailing 12-Months
Company Description
3D Medicines, Inc.
3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.
---
Technical Analysis
Ping An Insurance Company of China
―
3SBio
―
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
---